Search Follow us
Refine By

Stock Exchange


Type of Publication

canfite biopharma

1 - 8 of 8
Sort by: popularity | newest
Page  of 1
Can-Fite BioPharma

Termination of coverage

Update | Pharmaceuticals & healthcare | 15 Dec 2014

Edison Investment Research is terminating coverage on Can-Fite BioPharma (CANFY). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Can-Fite BioPharma

Awaiting future catalysts

Update | Pharmaceuticals & healthcare | 01 Jul 2014

Can-Fite's lead compound CF101 is continuing to advance in a Phase II/III study in psoriasis, with top-line data now expected in Q115. The company is also working on finalising a Phase III protocol for this candidate in rheumatoid arthritis (RA), although we continue to anticipate a partnership will be necessary before starting such a trial. Our new $88m rNPV (vs $90m previously) reflects minor adjustments in the timing of potential market introductions in RA and psoriasis, and continues to reflect significant upside to the current EV of $24m. The next major catalyst in H214 could be a licensing agreement (US and/or Europe) for CF101.


Edison healthcare quarterly: It’s getting personal

Sector Commentary: | Pharmaceuticals & healthcare | 30 Jun 2014



Edison healthcare quarterly: A boost for allergy immunotherapy

Sector Commentary: | Pharmaceuticals & healthcare | 05 Mar 2014


Can-Fite BioPharma

One step forward, one step back

Update | Pharmaceuticals & healthcare | 22 Jan 2014

Can-Fite's lead compound CF101 met its primary endpoint in a Phase IIb study in rheumatoid arthritis (RA), but was unsuccessful in meeting endpoints in the dry eye syndrome (DES) Phase III trial. We have increased our probability of commercial success in RA to 20% (from 15%) and have removed DES from our valuation, as the likelihood of commercial viability appears remote. Our new $90m rNPV (vs $99m previously) continues to reflect significant upside to the current EV of $40m. The next major catalyst in H114 could be a licensing agreement (US and/or Europe) for CF101, which would also help to determine the next clinical steps in RA.

Can-Fite BioPharma

Funding prompts a look at CF102

Update | Pharmaceuticals & healthcare | 13 Nov 2013

Can-Fite's $6m equity offering provides the funds to support its ongoing and planned clinical studies, in particular a Phase II study for CF102 in hepatocellular carcinoma (HCC). We now include this asset in our valuation model, which raises Can-Fite's rNPV pipeline to $99.1m from $86m. The per-basic ADR valuation also increases to $13.38 (vs $12.60) after including Q313 net cash and the $6m financing. Lead candidate CF101 remains the key near-term valuation driver and study readouts in December 2013 o Phase IIb in rheumatoid arthritis and Phase III for dry eye syndrome o could re-rate the stock and help secure new partners.

Futura Medical

Edison healthcare quarterly: Immuno-oncology 2: The combos come

Sector Commentary: | Pharmaceuticals & healthcare | 06 Nov 2013


Can-Fite BioPharma

Leveraging the A3AR platform

Initiation | Pharmaceuticals & healthcare | 23 Oct 2013

Can-Fite's investment case rests on the prospects for novel orally bioavailable A3 adenosine receptor (A3AR) agonist, CF101, in trials for blockbuster potential inflammatory conditions, including rheumatoid arthritis (RA) and psoriasis. Positive Phase II data have been shown in psoriasis and dry eye syndrome (DES). Our $86m rNPV for the psoriasis, RA and DES programmes exceeds the current EV of $45m. Clinical study readouts from a Phase IIb study in RA and a Phase III programme in DES are expected in December 2013, which if positive, could trigger value-enhancing partnership negotiations and provoke a re-rating in the stock.